03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
22:47 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Idiopathic thrombocytopenic purpura (ITP); rheumatoid arthritis (RA); autoimmune In vitro and mouse studies suggest an Fc trimer that binds FCGR1 and FCGR2 could help treat ITP, RA and other autoimmune diseases. The trimer consisted...
07:00 , Jun 15, 2015 |  BioCentury  |  Emerging Company Profile

Maximizing immunogenicity

OncoQR ML is developing allogeneic cancer vaccines that use S-TIR active immunotherapy technology to increase immunogenicity compared with earlier approaches. According to co-founder, Managing Director and COO Christof Langer, the company's "warhead" approach enables a...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

Pikamab Inc., Hospital for Special Surgery deal

Pikamab received exclusive, worldwide rights to the hospital's U.S. patents covering polymorphisms in the FC gamma receptor (FCGR) genes. The deal includes U.S. Patent No. 5,830,652, which covers methods to determine the severity of lupus...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Prima, AstraZeneca deal

AZN and PRR's Arthron Pty Ltd. subsidiary extended to June 30, 2006, their 2004 deal to study Arthron's Fc receptor technology. PRR said the Fc gamma receptor IIa (CD32) is a target for autoimmune diseases,...
01:12 , Jun 24, 2005 |  BC Extra  |  Clinical News

Researchers publish CRP pathway

Researchers at UC Davis published in the July issue of Arteriosclerosis, Thrombosis, and Vascular Biology the mechanism through which C-reactive protein (CRP) enters human aortic endothelial cells (HAECs). The study showed that CRP enters HAECs...
08:00 , Nov 3, 2003 |  BioCentury  |  Tools & Techniques

Cause without effect

In autoimmune disease, companies aiming to squelch the damage induced by auto-antibodies have two options: stop auto-antibody production or stop their impact on targeted tissue. By focusing on CD16, MacroGenics Inc. has chosen the latter,...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Company News

University of Pennsylvania other research news

Scientists reported in Nature Biotechnology the generation of aAPCs and their use in stimulating the growth of cytotoxic T cells (CTLs). aAPCs consisting of an erythromyeloid cell line expressing CD32 and the 4-1BB ligand and...